Beligas Semaglutide 5MG vial






1 vial


Application areas

Semaglutide for sale is a long-acting dosage form developed based on the basic structure of liraglutide, which is more effective in treating type 2 diabetes. Therefore, it is mainly used in the medical field and clinical research.

Semaglutide has hypoglycemic effects, is a long-acting glucagon-like peptide 1 (GLP-1) analog, an agonist of the GLP-1 receptor, and has the potential to treat type 2 diabetes (T2DM). effect.


1. Pancreatitis: In the glycemic control trial, pancreatitis was reported as a serious adverse event in 6 patients receiving RYBELSUS (0.1 events per 100 patient-years) compared with 1 patient in the control group (<0.1 event per 100 patient-years). events). After starting RYBELSUS, watch patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting). If pancreatitis is suspected, RYBELSUS should be discontinued and appropriate treatment initiated; if pancreatitis is confirmed, RYBELSUS should be discontinued.

2. Complications of diabetic retinopathy: In the pooled analysis of the RYBELSUS glycemic control trial, patients reported adverse reactions related to diabetic retinopathy during the trial (4.2% in the RYBELSUS group and 3.8% in the control group). Rapid improvements in glycemic control are associated with temporary worsening of diabetic retinopathy. The long-term glycemic control effects of semaglutide on complications of diabetic retinopathy have not been studied. Patients with a history of diabetic retinopathy should be monitored for the progression of diabetic retinopathy.

3. Hypoglycemia occurs with concomitant use of insulin secretagogues or insulin: RYBELSUS combined with insulin secretagogues (such as sulfonylurea drugs) or insulin treatment may increase the patient’s risk of hypoglycemia, including severe hypoglycemia. Lowering the dose of the sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin may reduce the risk of hypoglycemia. Inform patients of the risk of hypoglycemia while taking these drugs and make them aware of the signs and symptoms of hypoglycemia.

4. Acute kidney injury: In some post-marketing reports, patients treated with GLP-1 receptor agonists (including semaglutide) have experienced acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis. These events have also been reported in some patients without known underlying kidney disease. Most of these events occur in patients who experience nausea, vomiting, diarrhea, or dehydration. Renal function should be monitored in patients who report serious gastrointestinal adverse reactions when initiating or increasing the dose of RYBELSUS.

5. Allergic reactions: Patients receiving RYBELSUS treatment have reported serious allergic reactions (such as anaphylaxis, angioedema). If an allergic reaction occurs, discontinue use of RYBELSUS; treat promptly according to standard of care, and monitor until signs and symptoms resolve. It should not be used in patients with previous hypersensitivity to RYBELSUS. GLP-1 receptor agonists can cause allergic reactions and angioedema. Caution should be used in patients who develop angioedema or anaphylaxis after taking another GLP-1 receptor agonist, as it is unknown whether such patients are more likely to develop anaphylaxis after taking RYBELSUS.

6. Pregnancy: May cause fetal harm.

7. Lactation period: Breastfeeding is not recommended.

8. Females and males of reproductive potential: Discontinue RYBELSUS at least 2 months before planned pregnancy.




There are no reviews yet.

Be the first to review “Beligas Semaglutide 5MG vial”

Your email address will not be published. Required fields are marked *